Serum Bcl-2-Associated Athanogene 2 Levels as a Potential Prognostic Indicator in Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Journal of Breast Cancer · 2026 · 29
DOI: 10.4048/jbc.2026.0157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Breast Cancer, 2026. Verfasst von Soong June Bae und 7 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Bae, S. J., Kim, J. H., Kook, Y., Ahn, S. G., Kim, H., Kang, D. W., Kim, S., & Jeong, J. (2026). Serum Bcl-2-Associated Athanogene 2 Levels as a Potential Prognostic Indicator in Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy. Journal of Breast Cancer, 29. https://doi.org/10.4048/jbc.2026.0157
Vancouver
Bae SJ, Kim JH, Kook Y, Ahn SG, Kim H, Kang DW, et al. Serum Bcl-2-Associated Athanogene 2 Levels as a Potential Prognostic Indicator in Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy. Journal of Breast Cancer. 2026;29. doi:10.4048/jbc.2026.0157
BibTeX
@article{Bae2026,
author = {Bae, Soong June and Kim, Jee Hung and Kook, Yoonwon and Ahn, Sung Gwe and Kim, Hyejin and Kang, Dong Woo and Kim, Seong-Jin and Jeong, Joon},
title = {Serum Bcl-2-Associated Athanogene 2 Levels as a Potential Prognostic Indicator in Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy},
journal = {Journal of Breast Cancer},
year = {2026},
volume = {29},
doi = {10.4048/jbc.2026.0157}
}
EUVIMED